| (1) |
Adams DD, Purves HD. Abnormal responses in the assay of thyrotrophin.
Proc Univ Otago Med Sch 1956; 34: 11-2. |
| (2) |
Kriss JP, Pleshakov V, Chien JR. Isolation and identification of the long-acting
thyroid stimulator and its relation to hyperthyroidism and circumscribed
pretibial myxedema. J Clin Endocrinol 1964; 24: 1005-28. |
| (3) |
Rapoport B, Chazenbalk GD, Jaume JC, McLachlan SM. he thyrotropin (TSH)receptor:interaction
with TSH and autoantibodies. Endocr Rev 1998;19:673-716.[Erratum,Endocr
Rev 1999;20:100.] |
| (4) |
Weetman AP, DeGroot L. Autoimmunity to the thyroid gland.In:
Thyroid disease manager. Chicago: Endocrine Education, 1999. (See http://www.thyroidmanager.org/)
(See NAPS document no. 05570 for 30 pages, c/o Microfiche Publications,
248 Hempstead pke., West Hempstead, NY 11552.) |
| (5) |
Takata I, Suzuki Y, Saida K, Sato. Human thyroid stimulating activity
and clinical state in antithyroid treatment of juvenile Graves disease.
Acta Endocrinol(Copenh)1980; 94: 46-52. |
| (6) |
LiVolsi VA. Pathology. In: Braverman LE, Utiger RD, eds. Werner and Ingbar's
the thyroid. 8th ed. Philadelphia: Lippincott Williams &Wilkins, 2000: 488-511. |
| (7) |
Weetman AP, McGregor AM, Wheeler MH, Hall R.Extrathyroidal sites of autoantibody
synthesis in Graves disease. Clin Exp Immunol 1984; 56: 330-6. |
| (8) |
Young RJ, Sherwood MB, Simpson JG, Nicol AG, Michie W, Beck JS. Histometry
of lymphoid infiltrate in the thyroid of primary thyrotoxicosis patients:relation
of extent of thyroiditis to preoperative drug treatment and preoperative
hypothyroidism. J Clin Pathol 1976; 29: 398-402. |
| (9) |
Paschke R, Ludgate M.he thyrotropin receptor in thyroid diseases. N Engl
J Med 1997; 337: 1675-81. |
| (10) |
McLachlan SM, Rapoport B.Monoclonal, human autoantibodies to the TSH receptor
- the Holy Grail and why are we looking for it? J Clin Endocrinol Metab
1996; 81: 3152-4. |
| (11) |
Chazenbalk GD, Wang Y, Guo J, et al. A mouse monoclonal antibody to a
thyrotropin receptor ectodomain variant provides insight into the exquisite
antigenic conformational requirement, epitopes and in vivo concentration
of human autoantibodies. J Clin Endocrinol Metab 1999; 84: 702-10. |
| (12) |
Kosugi S, Ban, Akamizu, Valente W, Kohn LD. Use of thyrotropin receptor(TSHR)mutants
to detect stimulating TSHR antibodies in hypothyroid patients with idiopathic
myxedema, who have blocking TSHR antibodies. J Clin Endocrinol Metab 1993;
77: 19-24. |
| (13) |
Martin A, Nakashima M, Zhou A, Aronson D, Werner AJ, Davies TF. Detection
of major T cell epitopes on human thyroid stimulating hormone receptor by
overriding immune heterogeneity in patients with Graves disease. J Clin
Endocrinol Metab 1997; 82: 3361-6. |
| (14) |
Di Paola R, Menzaghi C, De Filippis V, Corda D, Di Cerbo A. Cyclooxygenase-dependent
thyroid cell proliferation induced by immunoglobulins from patients with
Graves disease. J Clin Endocrinol Metab 1997; 82: 670-3. |
| (15) |
Bottazzo GF, Pujol-Borrell R, Hanafusa, Feldmann M. Role of aberrant HLA-DR
expression and antigen presentation in induction of endocrine autoimmunity.
Lancet 1983; 2: 1115-9. |
| (16) |
Marelli-Berg FM, Weetman AP, Frasca L, et al. Antigen presentation by
epithelial cells induces anergic immunoregulatory CD45R0+T cells and deletion
of CD45RA+T cells. J Immunol 1997; 159: 5853-61. |
| (17) |
Heufelder AE. Pathogenesis of Graves ophthalmopathy: recent controversies
and progress. Eur J Endocrinol 1995; 132: 532-41. |
| (18) |
Small RG. Enlargement of levator palpebrae superioris muscle fibers in
Graves ophthalmopathy. Ophthalmology 1989; 96: 424-30. |
| (19) |
Peacey SR, Flemming L, Messenger A, Weetman AP. Is Graves ﾕdermopathy
a generalized disorder? Thyroid 1996; 6: 41-5. |
| (20) |
Bahn RS, Heufelder AE. Pathogenesis of Graves ophthalmopathy. N Engl J
Med 1993; 329: 1468-75. |
| (21) |
Bahn RS, Dutton CM, Natt N, Joba W, Spitzweg C, Heufelder AE. hyrotropin
receptor expression in Graves ﾕorbital adipose/connective tissues:potential
autoantigen in Graves ophthalmopathy. J Clin Endocrinol Metab 1998; 83:
998-1002. |
| (22) |
Many M-C, Costagliola S, Detrait M, Denef F, Vassart G, Ludgate MC. Development
of an animal model of autoimmune thyroid eye disease. J Immunol 1999; 162:
4966-74. |
| (23) |
Gunji K, Kubota S, Swanson J, et al. Role of the eye muscles in thyroid
eye disease: identification of the principal autoantigens. hyroid 1998;
8: 553-6. [Erratum, Thyroid 1998; 8: 1079.] |
| (24) |
Brix TH, Kyvik KO, Hegedus L. What is the evidence of genetic factors
in the etiology of Graves disease? A brief review. hyroid 1998; 8: 627-34. |
| (25) |
Heward JM, Allahabadia A, Daykin J, et al.Linkage disequilibrium between
the human leukocyte antigen class II region of the major histocompatibility
complex and Graves disease: replication using a population case control
and family-based study. J Clin Endocrinol Metab 1998; 83: 3394-7. |
| (26) |
Chen Q-Y, Huang W, She J-X, Baxter F, Volpe R, Maclaren MK. HLA-DRB1*08,
DRB1*03/DRB3*0101, and DRB3*0202 are susceptibility genes for Graves ﾕdisease
in North American Caucasians, whereas DRB1*07 is protective. J Clin Endocrinol
Metab 1999; 84: 3182-6. |
| (27) |
Yanagawa, Hidaka Y, Guimaraes V, Soliman M, DeGroot LJ. CTLA-4 gene polymorphism
associated with Graves disease in a Caucasian population. J Clin Endocrinol
Metab 1995; 80: 41-5. |
| (28) |
omer Y, Barbesino G, Greenberg DA, Concepcion E, Davies F. Linkage analysis
of candidate genes in autoimmune thyroid disease.III. Detailed analysis
of chromosome 14 localizes Graves ﾕdisease-1(GD-1) close to multinodular
goiter-1(MNG-1). J Clin Endocrinol Metab 1998; 83: 4321-7. |
| (29) |
Idem. A new Graves disease-susceptibility locus maps to chromosome 20q11.2.Am
J Hum Genet 1998; 63: 1749-56. |
| (30) |
Barbesino G, omer Y, Concepcion ES, Davies F, Greenberg DA. Linkage analysis
of candidate genes in autoimmune thyroid disease.II. Selected gender-related
genes and the X-chromosome. J Clin Endocrinol Metab 1998; 83: 3290-5. |
| (31) |
Chiovato L, Pinchera L. Stressful life events and Graves disease. Eur
J Endocrinol 1996; 134: 680-2. |
| (32) |
Bartalena L, Bogazzi F, anda ML, Manetti L, Dell ﾕUnto E, Martino E. Cigarette
smoking and the thyroid. Eur J Endocrinol 1995; 133: 507-12. |
| (33) |
Barclay ML, Brownlie BEW, urner JG, Wells JE. Lithium associated thyrotoxicosis:
a report of 14 cases, with statistical analysis of incidence. Clin Endocrinol(Oxf)1994; 40: 759-64. |
| (34) |
Gilquin J, Viard J-P, Jubault V, Sert C, Kazatchkine MD. Delayed occurrence
of Graves disease after immune restoration with HAAR: highly active antiretroviral
therapy. Lancet 1998; 352: 1907-8. |
| (35) |
Coles AJ, Wing MG, Smith S, et al. Pulsed monoclonal antibody treatment
and autoimmune thyroid disease in multiple sclerosis. Lancet 1999; 354:
1691-5. |
| (36) |
omer Y, Davies F. Infection, thyroid disease, and autoimmunity. Endocr
Rev 1993; 14: 107-20. |
| (37) |
Vanderpump MPJ, unbridge WMG. he epidemiology of autoimmune thyroid disease.
In: Volp R, ed. Autoimmune endocrinopathies. Vol.15 of Contemporary endocrinology.
otowa, N. J. : Humana Press, 1999: 141-62. |
| (38) |
Jacobson DL, Gange SJ, Rose NR, Graham NM. Epidemiology and estimated
population burden of selected autoimmune diseases in the United States.
Clin Immunol Immunopathol 1997; 84: 223-43. |
| (39) |
Kendall-aylor P. hyrotoxicosis. In: Grossman A, ed. Clinical endocrinology.
Oxford, England: Blackwell Science, 1998: 328-58. |
| (40) |
Nordyke RA, Gilbert FI Jr, Harada ASM.Graves ﾕdisease: influence of age
on clinical findings. Arch Intern Med 1988; 148: 626-31. |
| (41) |
Villadolid MC, Yokoyama N, Izumi M, et al. Untreated Graves ﾕdisease patients
without clinical ophthalmopathy demonstrate a high frequency of extraocular
muscle(EOM)enlargement by magnetic resonance. J Clin Endocrinol Metab 1995;
80: 2830-3. |
| (42) |
Perros P, Crombie AL, Matthews JNS, Kendall-aylor P. Age and gender influence
the severity of thyroid-associated ophthalmopathy: a study of 101 patients
attending a combined thyroid-eye clinic.Clin Endocrinol (Oxf)1993; 38:
367-72. |
| (43) |
ellez M, Cooper J, Edmonds C. Graves ophthalmopathy in relation to cigarette
smoking and ethnic origin. Clin Endocrinol (Oxf)1992; 36: 291-4. |
| (44) |
Mourits MP, Prummel MF, Wiersinga WM, Koornneef L. Clinical activity score
as a guide in the management of patients with Graves ophthalmopathy. Clin
Endocrinol (Oxf)1997; 47: 9-14. [Erratum,Clin Endocrinol (Oxf)1997; 47:
632.] |
| (45) |
Fatourechi V, Pajouhi M, Fransway AF. Dermopathy of Graves disease (pretibial
myxedema): review of 150 cases. Medicine (Baltimore)1994; 73: 1-7. |
| (46) |
Singer PA, Cooper DS, Levy EG, et al. reatment guidelines for patients
with hyperthyroidism and hypothyroidism. JAMA 1995; 273: 808-12. |
| (47) |
Carnell NE, Valente WA. hyroid nodules in Graves disease: classification,
characterization, and response to treatment. hyroid 1998; 8: 647-52. [Erratum,
hyroid 1998; 8: 1079.] |
| (48) |
Davies F, Roti E, Braverman LE, DeGroot LJ. hyroid controversy-stimulating
antibodies. J Clin Endocrinol Metab 1998; 83: 3777-85. |
| (49) |
Rees Smith B, McLachlan SM, Furmaniak J. Autoantibodies to the thyrotropin
receptor. Endocr Rev 1988; 9: 106-21. |
| (50) |
Costagliola S, Morgenthaler NG, Hoermann R, et al. Second generation assay
for thyrotropin receptor antibodies has superior diagnostic sensitivity
for Graves disease. J Clin Endocrinol Metab 1999; 84: 90-7. |
| (51) |
Vitti P, Elisei R, onacchera M, et al. Detection of thyroid-stimulating
antibody using Chinese hamster ovary cells transfected with cloned human
thyrotropin receptor. J Clin Endocrinol Metab 1993; 76: 499-503. |
| (52) |
Weetman AP, Wiersinga WM. Current management of thyroid-associated ophthalmopathy
in Europe:results of an international survey. Clin Endocrinol (Oxf)1998;
49: 21-8. |
| (53) |
Utech CI, Khatibnia U, Winter PF, Wulle KG. MR T2 relaxation time for
the assessment of retrobulbar inflammation in Graves ophthalmopathy. hyroid
1995; 5: 185-93. |
| (54) |
Krassas GE, Kahaly GJ. he role of octreoscan in thyroid eye disease. Eur
J Endocrinol 1999; 140: 373-5. |
| (55) |
amai H, Kasagi K, akaichi Y, et al. Development of spontaneous hypothyroidism
in patients with Graves disease treated with antithyroidal drugs: clinical,
immunological, and histological findings in 26 patients. J Clin Endocrinol
Metab 1989; 69: 49-53. |
| (56) |
Prummel MF, Wiersinga WM, Mourits MP, Koornneef L, Berghout A, van der
Gaag R. Effect of abnormal thyroid function on the severity of Graves ophthalmopathy.
Arch Intern Med 1990; 150: 1098-101. |
| (57) |
Perros P, Crombie AL, Kendall-aylor P. Natural history of thyroid associated
ophthalmopathy. Clin Endocrinol (Oxf)1995; 42: 45-50. |
| (58) |
Gerding MN, erwee CB, Dekker FW, Koornneef L, Prummel MF, Wiersinga WM.
Quality of life in patients with Graves ophthalmopathy is markedly decreased:measurement
by the Medical Outcomes Study instrument. hyroid 1997; 7: 885-9. |
| (59) |
Franklyn JA.he management of hyperthyroidism. N Engl J Med 1994; 330:
1731-8. [Erratum, N Engl J Med 1994; 331: 559.] |
| (60) |
Burch HB, Wartofsky L. Graves ophthalmopathy: current concepts regarding
pathogenesis and management. Endocr Rev 1993; 14: 747-93. |
| (61) |
Prummel MF, Wiersinga WM. Immunomodulatory treatment of Graves ophthalmopathy.
hyroid 1998; 8: 545-8. |
| (62) |
Vitti P, Rago, Chiovato L, et al. Clinical features of patients with Graves
disease undergoing remission after antithyroid drug treatment. hyroid 1997;
7: 369-75. |
| (63) |
Maugendre D, Gatel A, Campion L, et al. Antithyroid drugs and Graves disease
ﾑprospective randomised assessment of long-term treatment. Clin Endocrinol
(Oxf)1999; 50: 127-32. |
| (64) |
Weetman AP, Pickerill AP, Watson P, Chatterjee VK, Edwards OM. reatment
of Graves disease with the block-replace regimen of antithyroid drugs: the
effect of treatment duration and immunogenetic susceptibility on relapse.
QJM 1994; 87: 337-41. |
| (65) |
Hashizume K, Ichikawa K, Sakurai A, et al. Administration of thyroxine
in treated Graves disease: effects on the level of antibodies to thyroidstimulating
hormone receptors and on the risk of recurrence of hyperthyroidism. N Engl
J Med 1991; 324: 947-53. |
| (66) |
McIver B, Rae P, Beckett G, Wilkinson E, Gold A, oft A. Lack of effect
of thyroxine in patients with Graves hyperthyroidism who are treated with
an antithyroid drug. N Engl J Med 1996; 334: 220-4. |
| (67) |
International Agranulocytosis and Aplastic Anaemia Study. Risk of agranulocytosis
and aplastic anaemia in relation to use of antithyroid drugs. BMJ 1988;
297: 262-5. |
| (68) |
oft AD, Weetman AP. Screening for agranulocytosis in patients treated
with antithyroid drugs. Clin Endocrinol (Oxf)1998; 49: 271. |
| (69) |
Fukata S, Kuma K, Sugawara M. Granulocyte colony-stimulating factor(G-CSF)does
not improve recovery from antithyroid drug-induced agranulocytosis: a prospective
study. Thyroid 1999; 9: 29-31. |
| (70) |
Williams KV, Nayak S, Becker D, Reyes J, Burmeister LA. Fifty years of
experience with propylthiouracil-associated hepatotoxicity: what have we
learned? J Clin Endocrinol Metab 1997; 82: 1727-33. |
| (71) |
Solomon B, Glinoer D, Lagasse R, Wartofsky L. Current trends in the management
of Graves disease. J Clin Endocrinol Metab 1990; 70: 1518-24. |
| (72) |
Levy EG. reatment of Graves disease: the American way. Baillieres Clin
Endocrinol Metab 1997; 11: 585-95. |
| (73) |
Ljunggren J-G, Torring O, Wallin G, et al. Quality of life aspects and
costs in treatment of Graves hyperthyroidism with antithyroid drugs, surgery,
or radioiodine: results from a prospective, randomized study. hyroid 1998;8:653-9. |
| (74) |
Bartalena L, Marcocci C, Bogazzi F, et al. Relation between therapy for
hyperthyroidism and the course of Graves ophthalmopathy. N Engl J Med 1998;
338: 73-8. |
| (75) |
Bartalena L, Marcocci C, anda ML, et al. Cigarette smoking and treatment
outcomes in Graves ophthalmopathy. Ann Intern Med 1998; 129: 632-5. |
| (76) |
Hall P, Lundell G, Holm L-E. Mortality in patients treated for hyperthyroidism
with iodine-131. Acta Endocrinol (Copenh)1993; 128: 230-4. |
| (77) |
Franklyn JA, Maisonneuve P, Sheppard MC, Betteridge J, Boyle P. Mortality
after the treatment of hyperthyroidism with radioactive iodine. N Engl J
Med 1998; 338: 712-8. |
| (78) |
Ron E, Doody MM, Becker DV, et al. Cancer mortality following treatment
for adult hyperthyroidism. JAMA 1998; 280: 347-55. |
| (79) |
Franklyn JA, Maisonneuve P, Sheppard MC, Betteridge J, Boyle P. Cancer
incidence and mortality after radioiodine treatment for hyperthyroidism:
a population-based cohort study. Lancet 1999; 353: 2111-5. |
| (80) |
Rivkees SA, Sklar C, Freemark M. he management of Graves disease in children,
with special emphasis on radioiodine treatment. J Clin Endocrinol Metab
1998; 83: 3767-76. |
| (81) |
Aizawa Y, Yoshida K, Kaise N, et al.he development of transient hypothyroidism
after iodine-131 treatment in hyperthyroid patients with Graves disease:
prevalence, mechanism and prognosis. Clin Endocrinol (Oxf)1997; 46: 1-5. |
| (82) |
Chiovato L, Fiore E, Vitti P, et al. Outcome of thyroid function in Graves
patients treated with radioiodine: role of thyroid-stimulating and thyrotropin-blocking
antibodies and of radioiodine-induced thyroid damage. J Clin Endocrinol
Metab 1998; 83: 40-6. [Erratum, J Clin Endocrinol Metab 1998; 83: 2155.] |
| (83) |
Jarlov AE, Hegedus L, Kristensen L, Nygaard B, Hansen JM. Is calculation
of the dose in radioiodine therapy of hyperthyroidism worth while? Clin
Endocrinol (Oxf)1995; 43: 325-9. |
| (84) |
Farrar JJ, oft AD. Iodine-131 treatment of hyperthyroidism: current issues.
Clin Endocrinol (Oxf)1991; 35: 207-12. |
| (85) |
Imseis RE, Vanmiddlesworth L, Massie JD, Bush AJ, Vanmiddlesworth NR.
Pretreatment with propylthiouracil but not methimazole reduces the therapeutic
efficacy of iodine-131 in hyperthyroidism. J Clin Endocrinol Metab 1998;
83: 685-7. |
| (86) |
Chou F-F, Wang P-W, Huang SC. Results of subtotal thyroidectomy for Graves
disease. hyroid 1999; 9: 253-7. |
| (87) |
Marcocci C, Bruno-Bossio G, Manetti L, et al. he course of Graves ophthalmopathy
is not influenced by near total thyroidectomy: a case-control study. Clin
Endocrinol (Oxf)1999; 51: 503-8. |
| (88) |
Mandel SJ, Brent GA, Larsen PR. Review of antithyroid drug use during
pregnancy and report of a case of aplasia cutis. Thyroid 1994; 4: 129-33. |
| (89) |
Momotani N, Noh JY, Ishikawa N, Ito K.Effects of propylthiouracil and
methimazole on fetal thyroid status in mothers with Graves hyperthyroidism.
J Clin Endocrinol Metab 1997; 82: 3633-6. |
| (90) |
Wing DA, Millar LK, Koonings PP, Montoro MN, Mestman JH. A comparison
of propylthiouracil versus methimazole in the treatment of hyperthyroidism
in pregnancy. Am J Obstet Gynecol 1994; 170: 90-5. |
| (91) |
Kung AWC, Jones BM. A change from stimulatory to blocking antibody activity
in Graves disease during pregnancy. J Clin Endocrinol Metab 1998; 83: 514-8. |
| (92) |
Laurberg P, Nygaard B, Glinoer D, Grussendorf M, Orgiazzi J. Guidelines
for TSH-receptor antibody measurements in pregnancy:results of an evidence-based
symposium organized by the European hyroid Association. Eur J Endocrinol
1998; 139: 584-6. |
| (93) |
Bartalena L, Marcocci C, Pinchera A. Treating severe Graves ophthal-mopathy.
Baillieres Clin Endocrinol Metab 1997; 11: 521-36. |
| (94) |
Garrity JA, Fatourechi V, Bergstralh EJ, et al. Results of transantral
orbital decompression in 428 patients with severe Graves ophthalmopathy.
Am J Ophthalmol 1993; 116: 533-47. |